European Cancer Congress | Conference

Dr. Nghiem on Pembrolizumab for Advanced Merkel Cell Carcinoma

September 27th 2015

Paul Nghiem, MD, PhD, Michael Piepkorn Endowed Chair in Dermatology Research, professor of Dermatology/Medicine at Fred Hutchinson Cancer Research Center, University of Washington Medicine discusses a phase II trial investigating the PD-1 blockade pembrolizumab as first systemic therapy in patients with advanced Merkel cell carcinoma (MCC).

Nivolumab Before Ipilimumab Has Greater Efficacy, Similar AEs

September 27th 2015

Two strategies of sequential immunotherapy for advanced melanoma showed similar safety and tolerability but substantially different efficacy.

Dr. Toni Choueiri on Cabozantinib Versus Everolimus in Renal Cell Carcinoma

September 27th 2015

Toni Choueiri, MD, Clinical Director, Lank Center for Genitourinary Oncology Director, Kidney Cancer Center, Senior Physician at Dana-Farber Cancer Institute, discusses the results of the METEOR trial in advanced renal cell carcinoma (RCC).

Dr. Hisham Mehanna on Quality of Life Differences in Head and Neck Squamous Cell Cancer

September 26th 2015

Hisham Mehanna, MBChB, PhD, Chair, Head and Neck Surgery, Director, Institute of Head and Neck Studies and Education at University of Birmingham, discusses differences in the quality of life (QoL) and functional outcomes of treatment between HPV-positive and HPV-negative head and neck squamous cell cancer patients (HNSCC).

Most Brain Metastases Have Actionable Mutations Not Found in Primary Tumor

September 26th 2015

More than half of brain metastases harbored clinically actionable genetic alterations that were distinct from those associated with the primary tumor.

Dr. Philippe Ruszniewski on NETTER-1 Study Results

September 26th 2015

Philippe Ruszniewski, MD, Professor of Gastroenterology, Chief of Division of Gastroenterology and Pancreatology, University of Paris VII, Beaujon Hospital, discusses the results of the phase 3 NETTER-1 study.

Targeted Radionuclide Improves PFS Over Octreotide LAR in Midgut NETs

September 26th 2015

Treatment with the novel peptide receptor radionuclide therapy Lutathera significantly increased progression-free survival over octreotide LAR in patients with advanced midgut neuroendocrine tumors.

Everolimus May Be New Standard of Care in Advanced Lung, GI NETs

September 26th 2015

Treatment with everolimus was associated with a 52% improvement in median progression-free survival compared with placebo in patients with advanced lung and gastrointestinal neuroendocrine tumors.

Pembrolizumab Active in Advanced Nasopharyngeal Carcinoma

September 26th 2015

More than a fifth of patients with previously treated metastatic nasopharyngeal carcinoma showed a measurable response when treated with the immune checkpoint inhibitor pembrolizumab.

Trabectedin OS Data Unclear in Phase III Sarcoma Study

September 26th 2015

The final analysis of phase III data for trabectedin were consistent with interim results by showing a lack of improvement for the primary endpoint of overall survival in patients with advanced soft tissue sarcoma.

Nivolumab Extends Survival in Advanced Renal Cell Carcinoma

September 25th 2015

Nivolumab reduced the risk of death by 27% versus everolimus in patients with advanced renal cell carcinoma, improving overall survival by 5.4 months.

Second-Line Cabozantinib Improves PFS in Advanced RCC

September 25th 2015

Second-line treatment with cabozantinib reduced the risk of progression or death by 42% compared with everolimus in patients with advanced renal cell carcinoma.

Dr. GrÃ¼nwald on Tumor Remission in RCC

October 15th 2013

Viktor GrÃ¼nwald, MD, PhD, an attending physician at the Hannover Medical School, discusses tumor remission in patients with renal cell carcinoma (RCC).

Dr. George on Sunitinib in Renal Cell Carcinoma

October 10th 2013

Daniel J. George, MD, director, GU Oncology, Duke Cancer Institute, discusses the use of sunitinib to treat patients with renal cell carcinoma (RCC).

Dr. Camidge on AP26113 in Advanced Malignancies

October 7th 2013

D. Ross Camidge, MD, PhD, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies.

Dovitinib Fails as Third-Line Option in Kidney Cancer

October 3rd 2013

Dovitinib failed to meet the primary endpoint of improving progression-free survival versus sorafenib (Nexavar) in patients with heavily pretreated progressive renal cell carcinoma

Biomarkers Predict Prognosis for Patients With mCRPC

October 3rd 2013

A new biomarker panel taken 12 weeks after initiating treatment with abiraterone acetate plus prednisone can predict prognosis at 2 years in men with metastatic castration-resistant prostate cancer

Trebananib Shows Promise in Recurrent Platinum-Sensitive Ovarian Cancer

October 3rd 2013

Trebananib added to paclitaxel significantly improved progression-free survival in patients with recurrent ovarian cancer compared with placebo plus paclitaxel in the large international TRINOVA-1 trial.

Dr. Schmidinger on Targeted Agent Side Effects in RCC

October 2nd 2013

Manuela Schmidinger, MD, medical oncologist, Medical University of Vienna, discusses the management of side effects from targeted agents in renal cell cancer, including hypertension, diarrhea, and hand-foot syndrome.

Dr. Yoshino on U3-1565 and TAS-102 in Colorectal Cancer

October 2nd 2013

Takayuki Yoshino, MD, medical oncologist, National Cancer Center Hospital East, Chiba, Japan, discusses U3-1565 and TAS-102, two agents used to treat colorectal cancer.